| 000 | 01884 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516084026.0 | ||
| 264 | 0 | _c20120711 | |
| 008 | 201207s 0 0 eng d | ||
| 022 | _a1573-2568 | ||
| 024 | 7 |
_a10.1007/s10620-012-2136-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aXie, Bingru | |
| 245 | 0 | 0 |
_aSorafenib for treatment of hepatocellular carcinoma: a systematic review. _h[electronic resource] |
| 260 |
_bDigestive diseases and sciences _cMay 2012 |
||
| 300 |
_a1122-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review; Systematic Review | ||
| 650 | 0 | 4 | _aAntineoplastic Protocols |
| 650 | 0 | 4 |
_aBenzenesulfonates _xadministration & dosage |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xcomplications |
| 650 | 0 | 4 |
_aCell Proliferation _xdrug effects |
| 650 | 0 | 4 |
_aChemoembolization, Therapeutic _xmethods |
| 650 | 0 | 4 | _aHand-Foot Syndrome |
| 650 | 0 | 4 |
_aHepatitis, Viral, Human _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 |
_aLiver Cirrhosis _xcomplications |
| 650 | 0 | 4 |
_aLiver Neoplasms _xcomplications |
| 650 | 0 | 4 |
_aNeovascularization, Pathologic _xdrug therapy |
| 650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
| 650 | 0 | 4 | _aPhenylurea Compounds |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aPyridines _xadministration & dosage |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aReceptor Protein-Tyrosine Kinases _xmetabolism |
| 650 | 0 | 4 | _aSorafenib |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_araf Kinases _xmetabolism |
| 700 | 1 | _aWang, David H | |
| 700 | 1 | _aSpechler, Stuart Jon | |
| 773 | 0 |
_tDigestive diseases and sciences _gvol. 57 _gno. 5 _gp. 1122-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10620-012-2136-1 _zAvailable from publisher's website |
| 999 |
_c21654492 _d21654492 |
||